192 related articles for article (PubMed ID: 15474864)
1. Anti-interleukin-5 therapy for asthma and hypereosinophilic syndrome.
Kay AB; Klion AD
Immunol Allergy Clin North Am; 2004 Nov; 24(4):645-66, vii. PubMed ID: 15474864
[TBL] [Abstract][Full Text] [Related]
2. Rebound eosinophilia after treatment of hypereosinophilic syndrome and eosinophilic gastroenteritis with monoclonal anti-IL-5 antibody SCH55700.
Kim YJ; Prussin C; Martin B; Law MA; Haverty TP; Nutman TB; Klion AD
J Allergy Clin Immunol; 2004 Dec; 114(6):1449-55. PubMed ID: 15577851
[TBL] [Abstract][Full Text] [Related]
3. A review of treatment with mepolizumab, an anti-IL-5 mAb, in hypereosinophilic syndromes and asthma.
Busse WW; Ring J; Huss-Marp J; Kahn JE
J Allergy Clin Immunol; 2010 Apr; 125(4):803-13. PubMed ID: 20371394
[TBL] [Abstract][Full Text] [Related]
4. Anti-IL-5 and hypereosinophilic syndromes.
Sutton SA; Assa'ad AH; Rothenberg ME
Clin Immunol; 2005 Apr; 115(1):51-60. PubMed ID: 15870021
[TBL] [Abstract][Full Text] [Related]
5. Treatment of a case of pediatric hypereosinophilic syndrome with anti-interleukin-5.
Mehr S; Rego S; Kakakios A; Kilham H; Kemp A
J Pediatr; 2009 Aug; 155(2):289-91. PubMed ID: 19619754
[TBL] [Abstract][Full Text] [Related]
6. Targeting interleukin (IL) 5 for asthma and hypereosinophilic diseases.
Stein ML; Munitz A
Recent Pat Inflamm Allergy Drug Discov; 2010 Nov; 4(3):201-9. PubMed ID: 20807192
[TBL] [Abstract][Full Text] [Related]
7. Eosinophil-fibroblast interactions induce fibroblast IL-6 secretion and extracellular matrix gene expression: implications in fibrogenesis.
Gomes I; Mathur SK; Espenshade BM; Mori Y; Varga J; Ackerman SJ
J Allergy Clin Immunol; 2005 Oct; 116(4):796-804. PubMed ID: 16210053
[TBL] [Abstract][Full Text] [Related]
8. Anti-interleukin-5 antibody therapy in eosinophilic diseases.
Simon D; Braathen LR; Simon HU
Pathobiology; 2005; 72(6):287-92. PubMed ID: 16582580
[TBL] [Abstract][Full Text] [Related]
9. Therapeutic strategies for harnessing human eosinophils in allergic inflammation, hypereosinophilic disorders, and cancer.
Amini-Vaughan ZJ; Martinez-Moczygemba M; Huston DP
Curr Allergy Asthma Rep; 2012 Oct; 12(5):402-12. PubMed ID: 22875242
[TBL] [Abstract][Full Text] [Related]
10. Anti-interleukin-5 antibody therapy in asthma and allergies.
Corren J
Curr Opin Allergy Clin Immunol; 2011 Dec; 11(6):565-70. PubMed ID: 21971335
[TBL] [Abstract][Full Text] [Related]
11. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Garrett JK; Jameson SC; Thomson B; Collins MH; Wagoner LE; Freese DK; Beck LA; Boyce JA; Filipovich AH; Villanueva JM; Sutton SA; Assa'ad AH; Rothenberg ME
J Allergy Clin Immunol; 2004 Jan; 113(1):115-9. PubMed ID: 14699394
[TBL] [Abstract][Full Text] [Related]
12. Interleukin-2 primes eosinophil degranulation in hypereosinophilia and Wells' syndrome.
Simon HU; Plötz S; Simon D; Seitzer U; Braathen LR; Menz G; Straumann A; Dummer R; Levi-Schaffer F
Eur J Immunol; 2003 Apr; 33(4):834-9. PubMed ID: 12672048
[TBL] [Abstract][Full Text] [Related]
13. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics.
Flood-Page P; Menzies-Gow A; Phipps S; Ying S; Wangoo A; Ludwig MS; Barnes N; Robinson D; Kay AB
J Clin Invest; 2003 Oct; 112(7):1029-36. PubMed ID: 14523040
[TBL] [Abstract][Full Text] [Related]
14. Mepolizumab in eosinophilic disorders.
Abonia JP; Putnam PE
Expert Rev Clin Immunol; 2011 Jul; 7(4):411-7. PubMed ID: 21790283
[TBL] [Abstract][Full Text] [Related]
15. IL-5 and eosinophilia.
Takatsu K; Nakajima H
Curr Opin Immunol; 2008 Jun; 20(3):288-94. PubMed ID: 18511250
[TBL] [Abstract][Full Text] [Related]
16. [Biotherapies for the treatment of asthma: are they the treatment of the future?].
Tonnel AB; Denis G; Lelong J
Rev Mal Respir; 2006 Sep; 23(4 Pt 2):10S44-10S48. PubMed ID: 17127963
[No Abstract] [Full Text] [Related]
17. IL-17E upregulates the expression of proinflammatory cytokines in lung fibroblasts.
Létuvé S; Lajoie-Kadoch S; Audusseau S; Rothenberg ME; Fiset PO; Ludwig MS; Hamid Q
J Allergy Clin Immunol; 2006 Mar; 117(3):590-6. PubMed ID: 16522458
[TBL] [Abstract][Full Text] [Related]
18. Use of an anti-interleukin-5 antibody in the hypereosinophilic syndrome with eosinophilic dermatitis.
Plötz SG; Simon HU; Darsow U; Simon D; Vassina E; Yousefi S; Hein R; Smith T; Behrendt H; Ring J
N Engl J Med; 2003 Dec; 349(24):2334-9. PubMed ID: 14668459
[No Abstract] [Full Text] [Related]
19. Safety and efficacy of the monoclonal anti-interleukin-5 antibody SCH55700 in the treatment of patients with hypereosinophilic syndrome.
Klion AD; Law MA; Noel P; Kim YJ; Haverty TP; Nutman TB
Blood; 2004 Apr; 103(8):2939-41. PubMed ID: 15070668
[TBL] [Abstract][Full Text] [Related]
20. What targeting eosinophils has taught us about their role in diseases.
Bochner BS; Gleich GJ
J Allergy Clin Immunol; 2010 Jul; 126(1):16-25; quiz 26-7. PubMed ID: 20434203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
